EcoDrugPlus

Bruton Tyrosine Kinase

Ensembl ID : ENSCVAG00000004654
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSCVAG00000006636
Gene Symbol: LOC107104786
3 Cross references
190 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSCVAG00000008483
Gene Symbol: CCR9
3 Cross references
193 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSCVAG00000013668
Gene Symbol: CCR9
3 Cross references
193 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSCVAG00000008471
Gene Symbol: CXCR1
1 Cross references
275 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSCVAG00000010051
Gene Symbol: LOC107081721
2 Cross references
384 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSCVAG00000010017
Gene Symbol: LOC107081269
2 Cross references
391 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSCVAG00000010219
Gene Symbol: CFTR
3 Cross references
215 Possible Orthologues:

D(1)-Like Dopamine Receptor

Ensembl ID : ENSCVAG00000014316
Gene Symbol: LOC107094321
3 Cross references
199 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSCVAG00000003519
Gene Symbol: LOC107082767
3 Cross references
175 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSCVAG00000013611
Gene Symbol: DNMT1
3 Cross references
212 Possible Orthologues:

Dna Topoisomerase 1-Like

Ensembl ID : ENSCVAG00000001139
Gene Symbol: LOC107100266
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).